

ASX Release

Appendix 4C – Q4 2025 Quarterly Cash Flow Report

15 January 2026 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) ("Oneview" or "the Company"), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 31 December 2025 (Q4 25) and provided an update on business activities.

Financial Highlights

Oneview's cash balance at 31 December 2025 was €4.6 million (A\$8.1m) compared to €5.9 million (A\$10.5m) at 30 September 2025.

The Company had a net operating cash outflow of €1.4 million (A\$2.5 million) during the quarter compared to an operating outflow of €4.1 million in the same quarter of the prior year.

Key components of the net operating cash outflow in the quarter comprised:

- Receipts from customers totalled €3.5m (A\$6.3m), compared to €1.5 million in the prior year corresponding period due to higher revenue and the timing of receipts.
- Payments in respect of product manufacturing and operating costs of €1.1m (A\$2.0m) were €0.5 million lower than the prior year corresponding period. This is primarily due to higher outflows in Q4 2024 to acquire additional Chinese-manufactured OEM hardware to mitigate against the potential risks of changes in global tariffs at that time.
- Other operating costs including administration and corporate costs of €1.0 million (A\$1.8m) (Q4 2024: €1.1 million) and advertising and marketing costs of €60k (A\$106k) (Q4 2024: €251k) were lower than in the prior year corresponding period due to the timing of outflows.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates are included in item 6.1 of the Appendix 4C. Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees and salaries totalling €225,000 (A\$401,000).

Operational Activities

Sales and Customer Updates

The Company maintained strong commercial momentum during the fourth quarter of 2025 and added another new customer logo, Peterson Health in Kerryville, Texas. This 161-room facility has signed a 5-year contract with Oneview for our core platform and digital whiteboards spanning over 300 endpoints. In addition, effective today, 15 January 2026, Oneview's products have been added to the general purchasing organization of one of the ten largest health systems in the United States (as further detailed in the Baxter Partnership section below).

The Company deployed over 500 endpoints across several customers during Q4 2025 with year-end live endpoints at 14,880. A few minor deployments, which we expected to be completed by year-end, were delayed and will be completed during early 2026.

Implementation projects progressed at our customer sites, including:

- Deployments of the core platform, the digital door sign and the digital whiteboard continued during the final quarter of 2025 at Inova Health under the 1,900-bed Master Services Agreement which was signed in April 2024.
- 72 endpoints were deployed at Catholic Health's Good Samaritan hospital as part of our continuing expansion in this health system.
- Deployments were also completed at Citizen's Medical Center in Kansas and Sharp's Chula Vista Medical Center in California.

Baxter Partnership & Outlook

There has been significant progress with the Baxter partnership. Effective today, January 15, 2026, Baxter has finalised an amendment to Baxter's National Care Communication Agreement with the general purchasing organization of one of the United States ten largest health systems to include Oneview's products. This health system has over 85 hospitals and over 15,000 beds.

This is the first major health system Baxter has delivered access to under their partnership with Oneview, having already delivered contracts with several community and regional health systems, including Sharp Healthcare, Nicklaus Children's, Citizens Medical, Summit Health and Willis-Knighton.

This amendment positions Oneview within Baxter's National Care Communication Agreement framework with this Top 10 health system, enabling streamlined procurement for any hospital forming part of this health system. Any hospital within this health system can now purchase Oneview's products.

This development is strategically important for Oneview as it is the culmination of over two years of negotiation and product analysis, including comprehensive security review by the customer, and it paves the way for possible deployments at this system's hospitals. It should be noted that there is no guarantee that hospitals within the system will ultimately place orders for Oneview products. However, the Company is optimistic, following discussions in recent weeks, that purchase orders will progress over the coming months, with engagement initiated with three initial hospitals in three different states.

Oneview CEO, James Fitter, commented, "This is a textbook example of the patience and perseverance required to navigate the complexities of the largest US health systems and a key milestone for our Baxter partnership. These are large and complex organisations with multiple stakeholders that we would find extremely difficult to navigate without the experience and relationships that Baxter has built over many years. I also believe this development will provide further confidence and momentum across the Baxter sales organisation with respect to the quality and value of the Oneview product offering."

Overall, the Company maintained strong commercial momentum and continued to advance deployments during the fourth quarter of the year securing an additional customer logo and now gaining access to this Top 10 US health system. This strong commercial traction combined with enhanced deployment efficiency and speed, positions the Company favourably for 2026. We approach the year ahead with confidence and enthusiasm.

This announcement has been approved for release by the board of Oneview Healthcare plc.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, Ireland, the Middle East and Asia to unify the care experience, in over 80 hospitals.

Enquiries:

James Fitter, CEO

Darragh Lyons, CFO

Website : www.oneviewhealthcare.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")

31st December 2025

Consolidated statement of cash flows		Current quarter €'000	Year to date (12 months) €'000
1. Cash flows from operating activities			
1.1 Receipts from customers		3,517	12,592
1.2 Payments for			
(a) research and development		-	-
(b) product manufacturing and operating costs		(1,104)	(4,922)
(c) advertising and marketing		(60)	(259)
(d) leased assets		-	-
(e) staff costs		(2,744)	(11,771)
(f) administration and corporate costs		(1,026)	(4,207)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		7	28
1.5 Interest and other costs of finance paid		-	-
1.6 Income taxes (paid)/refunded		-	(1)
1.7 Government grants and tax incentives		37	481
1.8 Other (working capital movements)		(26)	(615)
1.9 Net cash from / (used in) operating activities		(1,400)	(8,674)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(49)	(107)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(49)	(107)

3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	-

Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	5,896	13,833
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(1,400)	(8,674)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(49)	(107)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	155	(450)
4.6	Cash and cash equivalents at end of period	4,602	4,602

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	4,602	5,896
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,602	5,896

6.	Payments to related parties of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	225
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	€'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,400)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,602
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,602
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	3.29
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/a	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/a	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:15 January 2026.....

Authorised by: **BY THE BOARD**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.